



[EMAIL](#)



[WEBSITE](#)



[TWITTER](#)

Welcome

Welcome to the second issue of the ICC-CTN Newsletter. As 2022 draws to a close, we are reflecting on another year of activities across the network. We have been busy with our current portfolio of 10 active trials, our new PPIE initiatives and activities, drafting reports and manuscripts, website updates, planning for future trials and more, as well as hosting our annual ICC-CTN meeting.

Thank you to all the network members in Ireland and beyond who have worked with us this year. Wishing you all a very Merry Christmas and a Happy New Year.

Alistair on behalf of the ICC-CTN Executive

Inside this Issue

- Recent news and activities
- 2022- A Year at the ICC-CTN
- Spotlight on- Public and Patient Involvement
- Current trials
- Closed trials
- What's to come: Upcoming Trials

Recent News and Activities



ICC-CTN Summer Meeting 2022: From L:R; Kathy Brickell, Belinda Howe, Sandra Peake and Alistair Nichol

The **ICC-CTN Summer meeting** went ahead in person at the Titanic Belfast in June this year after taking a two-year break during COVID-19. The meeting was highly enjoyable and a great success with colleagues from all over the world including Australia, Canada, the UK, US and Europe presenting talks on their CTN collaborative research activities and sharing global perspectives. Please **SAVE THE DATE for next year – 13th June 2023**. Looking forward to seeing you there and welcoming our international speakers, including Glenn Eastwood, Carol Hodgson, Ewan Golligher, and John Marshall to yet again co-host a session in collaboration with [InFACT](#).

The ICC-CTN are excited to be working on **Knowledge Translation Activities** for the TAME Trial and our Pandemic Program. As part of successful HRB awards this year, these initiatives are at the exciting stages of knowledge translation, exchange and dissemination and we are looking forward to sharing key learnings from these with you soon. Watch this space....


We have also received funding awards from St. Vincent's Anaesthetic Foundation for SPRINT SARI and public survey work on research in a pandemic, in addition to HRB Investigator led Project Funding, and over €7.5 million in leveraged international funding.

Just recently, the ICC-CTN were delighted to accept the award for **International Prize of the Year at the Irish Healthcare Awards 2022 for the Pandemic Resilience Program** of research which incorporates REMAP-CAP, SPRINT-SARI, GENOMIC and our PPIE program)

If you have visited the [ICC-CTN website](#) recently you will have seen the beginning of our website update and re-launch. The team have been working hard behind the scenes to give the website a fresh look, making it more navigable and a resource that can be harnessed equally by colleagues and the public.



2022- A year at the ICC-CTN



Spotlight on – Public Patient Involvement

At the ICC-CTN, one of our strategic objectives is to ensure the critically ill patient voice is heard and incorporated into our studies. 2022 has seen the expansion of our PPIE activities with the network now leading co-ordination in 3 PPI groups both nationally and internationally.

- ❖ CTN PPI**
 The ICC-PPI group has convened for this year's meetings remotely and have provided input and guidance on trial design and coordination such as providing feedback on patient facing documents and funding applications. This group is looking to expand from a Dublin base to a national group and we look forward to working with the national network of ICU teams in 2023 to grow the group. Please contact Leanne (leanne.hays@ucd.ie) to express your interest.
- ❖ ABI PPI**
 The network received seed funding from PPI Ignite to set up an Irish Acquired Brain Injury PPIE group in collaboration with Acquired Brain Injury Ireland. The group has already met remotely for their first regional meetings, with their second meetings planned for early January 2023. This is a really exciting collaboration.
- ❖ International Working Group**
 ICC-CTN team members are leading the global PPIE Working group which incorporates REMAP-CAP. This group has been meeting monthly throughout 2022. As part of this work, we will conduct empiric research by repeating our survey examining the public/patients' thoughts on research in a pandemic, now in a post-pandemic era. This survey is in the final stages of development and will be distributed in over 20 countries in early 2023.



Current Studies

EPO-Trauma – Expansion and Recruitment



European enrolment began in 2022 and there are currently 10 sites active in the EU, with 15 patients across these sites (global recruitment is at 288 over 27 sites). There are 10 more sites coordinated by the ICC-CTN to start in 2023.

REMAP-CAP- New Domains Alert

REMAP-CAP has had another paradigm shifting year in 2022 with over 11,897 patients enrolled and over 11 high-impact publications. Coming In early 2023, expressions of interest are sought for the new endothelial modulation, immune modulation (Influenza) and revised antiplatelet domains. The bacterial CAP antibiotic, macrolide and steroid domains are still recruiting. The HRB-ICC-CTN is through to stage 2 of the HRB DIFA funding round- fingers crossed.




SPRINT-SARI- Pandemic Mode de-activated



SPRINT SARI has now returned to inter-pandemic mode which means data collection will take place one week annually to capture important data on SARI patients. We encourage all the Irish sties to continue to participate in this important study, as COVID19 will not be our last pandemic. Funding has been received to continue to into 2023.

Closed Studies



TEAM- Completed, published (NEJM) and presented (ESICM 2022). Dissemination activities will continue in 2023 – watch this space!

REVIVAL- closed and results coming soon!

TAME - Manuscript and results due early 2023 – exciting times for the TAME Trial team! Come to our ICCCTN meeting in June 2023 to hear the results.

Upcoming Studies in 2023

Randomised Trials



STEP CARE- Sedation, Temperature and Pressure after Cardiac Arrest: A Factorial Randomized Trial with Three Interventions

Building on our successful out of hospital cardiac arrest program we are delighted to commence site set up for STEPCARE. We are working with our European partners to deliver this international, multicentre, parallel group, randomized, factorial (3x2), superiority trial amongst out of hospital cardiac arrest patients. Three intervention arms will be studied: Sedation, temperature and mean arterial pressure. The ICC-CTN will be helping to coordinate this study nationally, starting in Q2/3 2023.

PRACTICAL Platform and DRIVE RCT

A collaboration with our Canadian colleagues launching the PRACTICAL study- Platform of Randomized Adaptive Clinical Trials in Critical Illness in early 2023. Within the PRACTICAL platform sits an invasive mechanical ventilation strategies domain, and an intervention of driving pressures versus control which Ireland will participate in.



PRACTICAL
Platform Randomized Trial

SPICE IV: Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients

This is a Prospective, multi-centre, double-blind, placebo-controlled, randomized trial evaluating early sedation with DEX as the primary sedative on mortality and other key clinical outcomes in older patients in ICU. Based off a predefined sub-group analysis from the SPICE III trial, it is suggested that early sedation with dexmedetomidine as the primary sedative agent reduces 90-day all-cause mortality in ventilated critically ill patients who are ≥65 years old. There is a sample size of 3500 participants for this trial. Two Irish centres successfully recruited over 120 patients for SPICE III.



ARISE fluids- Fluid or vasopressors in Emergency Department Sepsis

A collaboration with colleagues in the ANZIC-RC and building on our participation in ARISE (NEJM 20), ARISE fluids will compare the effect of a restricted fluids strategy and early introduction of vasopressors to larger initial IV fluids volume with later introduction of vasopressors if required in patients admitted to the emergency department with septic shock.



MegaROX- The Mega Randomised Registry Trial Comparing Conservative vs. Liberal Oxygenation Targets and Logical

This trial is a randomised Interventional clinical trial aiming to recruit 40,000 patients and determine whether higher or lower oxygenation targets are more effective for patients receiving mechanical ventilation in an ICU. Approval has been obtained for the **Logical sub-study** – investigating the effects of a conservative oxygen regimen compared with a liberal oxygen regimen (comparator) on survival with a favourable neurological outcome at 180 days among mechanically ventilated ICU patients with suspected hypoxic ischemic following a cardiac arrest. This trial is funded by the ICC-CTN and the NHMRC.



Biological Samples Studies

GenOMICC-New Areas of Interest

Originally activated In Ireland for COVID-19, GenOMICC now has approval for Influenza, secondary pneumonia, cellulitis, primary pneumonia and pancreatitis. The HRB-ICC-CTN at UCD as the national co-ordinator for this study will establish an Irish database.



Industry Studies- Please contact us to learn more

All Studies are funded. Please contact iccctn@ucd.ie to express your interest in or ask about our current or upcoming studies